Bruker Corporation
$ 39.77
0.53%
24 Feb - close price
- Market Cap 6,042,700,000 USD
- Current Price $ 39.77
- High / Low $ 40.71 / 39.02
- Stock P/E N/A
- Book Value 16.27
- EPS -0.15
- Next Earning Report 2026-05-06
- Dividend Per Share $0.20
- Dividend Yield 0.51 %
- Next Dividend Date -
- ROA 0.02 %
- ROE N/A %
- 52 Week High 56.22
- 52 Week Low 28.46
About
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.
Analyst Target Price
$48.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-11-04 | 2025-08-04 | 2025-05-07 | 2025-02-13 | 2024-11-05 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.59 | 0.45 | 0.05 | 0.47 | 0.76 | 0.6 | 0.52 | 0.53 | 0.8 | 0.74 | 0.5 | 0.64 |
| Estimated EPS | 0.649 | 0.32 | 0.08 | 0.44 | 0.74 | 0.6 | 0.52 | 0.46 | 0.68 | 0.63 | 0.49 | 0.55 |
| Surprise | -0.059 | 0.13 | -0.03 | 0.03 | 0.02 | 0 | 0 | 0.07 | 0.12 | 0.11 | 0.01 | 0.09 |
| Surprise Percentage | -9.0909% | 40.625% | -37.5% | 6.8182% | 2.7027% | 0% | 0% | 15.2174% | 17.6471% | 17.4603% | 2.0408% | 16.3636% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.4164 |
| Currency | USD |
Previous Dividend Records
| Jan 2026 | Oct 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-01-02 | 2025-10-03 | 2025-06-27 | 2025-03-28 | 2024-12-16 | 2024-09-16 | 2024-06-17 | 2024-03-15 | 2023-12-15 | 2023-09-15 |
| Amount | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BRKR
2026-02-24 19:53:36
Bruker Corporation (NASDAQ: BRKR) is highlighted as one of the top 10 life sciences stocks according to hedge funds, despite recent price target reductions from Jefferies and BofA analysts. Both analysts maintained a "Buy" rating, citing potential for recovery in 2026, driven by improving conditions and strong second-half performance. The company specializes in scientific instruments and analytical solutions across various segments.
2026-02-24 11:53:36
Bruker Spatial Biology announced an expanded collaboration with Noetik Inc. to advance tissue foundational models using spatial molecular imaging (SMI). Noetik leverages Bruker's CosMx SMI platform to generate extensive spatial transcriptomic and multiomic datasets, aiming to scale toward one billion spatially resolved human cells to train advanced AI models for oncology and beyond. This partnership seeks to transform drug discovery and therapeutic applications by enabling complex genome-wide simulations of human cellular and tissue biology.
2026-02-23 12:00:10
Bruker has introduced new advancements in its Functional Proteomics 2.0 workflows for the timsOmni mass spectrometer, focusing on proteoform and PTM-resolved peptide variant analysis to deepen insights into disease biology. The company's updated software, including Bruker ProteoScape, OmniScape, and GlycoScape, leverages AI-enhanced de novo peptide sequencing and a novel OmniWave algorithm to improve identification of disease-driving proteoforms and enhance glycopeptide characterization. These developments aim to provide more detailed biological, disease, and drug discovery insights by moving beyond traditional protein lists.
2026-02-23 12:00:00
Bruker Corporation announced significant advancements in its spatial biology portfolio at the 2026 AGBT General Meeting, including the launch of the new CellScape XR spatial proteomics platform, the PaintScape 3D genome visualization platform now open for pre-orders, and an expanded CosMx mouse whole transcriptome panel. These innovations aim to provide comprehensive multiomic capabilities across DNA, RNA, and protein, enhancing scientific research from discovery to translational studies. Bruker also revealed plans for high-plex spatial miRNA and T-Cell Receptor assays, and introduced AI-ready analysis features for its AtoMx Spatial Informatics Platform, alongside a new collaboration with the University of Glasgow to study pancreatic cancer.
2026-02-23 11:47:02
Bruker Corporation unveiled significant advancements in its spatial biology portfolio at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting, introducing new platforms like CellScape XR for spatial proteomics and PaintScape for 3D genome visualization. The company is expanding capabilities for its CosMx Spatial Molecular Imager to include mouse whole transcriptome, miRNA, and TCR assays, alongside enhancements to its AtoMx Spatial Informatics Platform for AI-ready data. These innovations aim to provide researchers with comprehensive tools for high-fidelity spatial analysis, from discovery to translational research, exemplified by a major collaboration with the University of Glasgow on pancreatic cancer.
2026-02-19 14:03:30
Mark Munch, Executive Vice President and President of Bruker Nano Inc., exercised stock options for 2,000 Bruker (BRKR) shares at $22.19 per share on February 13, 2026. Following this, he sold 2,000 common shares at $36.94 per share under a Rule 10b5-1 trading plan. After these transactions, Munch directly owns 128,443 shares of Bruker common stock and holds 14,000 stock options.
